Intracellular Delivery III

Name: Intracellular Delivery III
Brand: Springer International Publishing AG
SKU: 9783319828466
Price: 824.66 RON
Availability: InStock

Market Entry Barriers of Nanomedicines

Autor: Ales Prokop, Volkmar Weissig

Limbă:

Legare: Carte broșată

Editura: Springer International Publishing AG

Disponibilitate: În depozitul extern

Expediem în 8-11 zile

824.66 lei

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emerg...

Informații despre carte

Autor

Ales Prokop, Volkmar Weissig

Limbă

engleză

Legare

Carte - Carte broșată

Publicat

2018

Pagini

453

EAN

9783319828466

Enbook ID

20118869

Editura

Springer International Publishing AG

Greutate

956

Dimensiuni

155 x 235 x 24

Descriere completă

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new "drugs" will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently "nanomaterials" have been said to "show promise" but none of these promises have so far been "reduced" to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug-carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.

S-ar putea să te intereseze

Clienții care au cumpărat această carte au mai cumpărat și

Cele mai căutate

Categories

Authors

Publishers

Produse

Produse

Cele mai căutate

Categories

Authors

Publishers

Produse

Produse

Intracellular Delivery III

Market Entry Barriers of Nanomedicines

Informații despre carte

Descriere completă

S-ar putea să te intereseze

Clienții care au cumpărat această carte au mai cumpărat și